Cargando…

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer

Prostate cancer is the most common cancer among men and the second leading cause of cancer-related deaths in men in the United States. The treatment paradigm for prostate cancer has evolved with the emergence of a variety of novel therapies which have improved survival; however, treatment-related to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zarrabi, Kevin K., Narayan, Vivek, Mille, Patrick J., Zibelman, Matthew R., Miron, Benjamin, Bashir, Babar, Kelly, William Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Advances in Prostate Cancer Diagnostics, Treatments and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285603/ https://www.ncbi.nlm.nih.gov/pubmed/37359737 http://dx.doi.org/10.1177/17562872231182219

Ejemplares similares

Normal preoperative endogenous testosterone levels predict prostate cancer progression in elderly patients after radical prostatectomy
por: Porcaro, Antonio Benito, et al.
Publicado: (2023)

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617
por: Crumbaker, Megan, et al.
Publicado: (2023)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2022)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2021)

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
por: Izumi, Kouji, et al.
Publicado: (2022)

Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
por: Guldvik, Ingrid Jenny, et al.
Publicado: (2022)

A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2021)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
por: de Groot, Ietsen, et al.
Publicado: (2021)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
por: Lendorf, Maria Elisabeth, et al.
Publicado: (2021)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
por: Lumen, Nicolaas, et al.
Publicado: (2021)

Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
por: Jasu, Juho, et al.
Publicado: (2021)

A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression
por: Wänman, Johan, et al.
Publicado: (2022)

Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy
por: Bommelaere, Thomas, et al.
Publicado: (2022)

Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment
por: Menges, Dominik, et al.
Publicado: (2023)

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race
por: Kensler, Kevin H., et al.
Publicado: (2022)

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
por: Welti, Jonathan, et al.
Publicado: (2016)

Automatic Avoidance Tendencies for Alcohol Cues Predict Drinking After Detoxification Treatment in Alcohol Dependence
por: Field, Matt, et al.
Publicado: (2016)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting
por: Donaldson, Ian A., et al.
Publicado: (2015)

Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy
por: Jensen, Lindsay, et al.
Publicado: (2017)

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017)

Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital
por: Kan, Carolyn K., et al.
Publicado: (2017)

Outcomes and toxicity from a prospective study of moderately hypofractionated radiation therapy for prostate cancer
por: Wang, Wei Gang, et al.
Publicado: (2017)

Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis
por: Markovina, Stephanie, et al.
Publicado: (2017)

Withania somnifera root extract inhibits fatty acid synthesis in prostate cancer cells
por: Kim, Su-Hyeong, et al.
Publicado: (2020)

Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes
por: Ben-Salem, Salma, et al.
Publicado: (2020)

Accuracy of Prostate Magnetic Resonance Imaging: Reader Experience Matters
por: Kang, Hyunseon C., et al.
Publicado: (2021)

Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance
por: Magnani, Christopher J., et al.
Publicado: (2020)

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
por: Sumanasuriya, Semini, et al.
Publicado: (2021)

Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry
por: Orabi, Hazem, et al.
Publicado: (2022)

Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
por: Press, Benjamin H., et al.
Publicado: (2022)

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer
por: Fischer-Valuck, Benjamin W., et al.
Publicado: (2022)

Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
por: Godtman, Rebecka Arnsrud, et al.
Publicado: (2021)

Prostate Cancer–specific Survival After Radical Prostatectomy Is Improved Among Metformin Users but Not Among Other Antidiabetic Drug Users
por: Joentausta, Roni M., et al.
Publicado: (2021)

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
por: Autio, Karen A., et al.
Publicado: (2021)

Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non–protocol-based Follow-up and a Protocol-based Contemporary Follow-up
por: Kalalahti, Inari, et al.
Publicado: (2021)

Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
por: Beckmann, Kerri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fnuib0ri84mcmv514mn4rno7q1